Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Cited by (2,893)

Items 201–300 of 2,893

1. How common is hyperkalaemia? A systematic review and meta-analysis of the prevalence and incidence of hyperkalaemia reported in observational studies
   Toby J L Humphrey, Mogamat Razeen Davids, Mogamat‐Yazied Chothia, Roberto Pecoits‐Filho, Carol A. Pollock, Glen James · 2021 · Clinical Kidney Journal
2. Synthesis of active pharmaceutical ingredients using electrochemical methods: keys to improve sustainability
   David Cantillo · 2021 · Chemical Communications
3. An IL-6/STAT3/MR/FGF21 axis mediates heart-liver cross-talk after myocardial infarction
   Jian-Yong Sun, Lin‐Juan Du, Xuerui Shi, Yuyao Zhang, Yuan Liu, Yong-Li Wang, Bo‐Yan Chen, Ting Liu, Hong Zhu, Yan Liu et al. · 2023 · Science Advances
4. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP‐1RA treatment: A subgroup analysis from the FIDELIO‐DKD trial
   Peter R Rossing, Rajiv Agarwal, Stefan D. Anker, Gerasimos S Filippatos, Bertram Pitt, Luis Miguel Ruilope, Aslam Amod, Michel Marre, Amer Joseph, Andrea Z. Lage et al. · 2021 · Diabetes Obesity and Metabolism
5. Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020
   Susanne B. Nicholas, Kenn B. Daratha, Radica Z. Alicic, Cami R. Jones, Lindsey M. Kornowske, Joshua J. Neumiller, Samuel Fatoba, Sheldon Xiaodong Kong, Rakesh Singh, Keith C. Norris et al. · 2023 · Diabetes Obesity and Metabolism
6. From Proteinuria to Fibrosis: An Update on Pathophysiology and Treatment Options
   Sonia Sharma, Brendan J Smyth · 2021 · Kidney & Blood Pressure Research
7. Finerenone: First Approval
   James E. Frampton · 2021 · Drugs
8. Effects of Short-Term Potassium Chloride Supplementation in Patients with CKD
   Martin Gritter, Rosa D. Wouda, Stanley M.H. Yeung, Michiel L. A. J. Wieërs, Frank Geurts, Maria A. J. de Ridder, Christian R. B. Ramakers, Liffert Vogt, Martin H. de Borst, Joris I. Rotmans et al. · 2022 · Journal of the American Society of Nephrology
9. Cardiorenal benefits of finerenone: protecting kidney and heart
   José Ramón González‐Juanatey, José Luis Górriz, Alberto Ortíz, Alfonso Valle, María José Soler, Lorenzo Fácila · 2023 · Annals of Medicine
10. Chronic Kidney Disease Progression—A Challenge
    Silvio Maringhini, Carmine Zoccali · 2024 · Biomedicines
11. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
    Ruolin Lv, Lili Xu, Lin Che, Song Liu, Yangang Wang, Bingzi Dong · 2023 · Frontiers in Endocrinology
12. Baseline Characteristics of Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction: The FINEARTS-HF Trial
    Scott David Solomon, John W. Ostrominski, Muthiah Vaduganathan, Brian Lee Claggett, Pardeep S. Jhund, Akshay Suvas Desai, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv Jayendra Shah et al. · 2024 · European Journal of Heart Failure
13. Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus
    Jin Sok Yu, Seung-Hwan Lee, Mee Kyoung Kim · 2022 · Endocrinology and Metabolism
14. Development and Validation of Prediction Models of Adverse Kidney Outcomes in the Population With and Without Diabetes
    Morgan Erika Grams, Nigel J. Brunskill, Shoshana H. Ballew, Yingying Sang, Josef Coresh, Kunihiro Matsushita, Aditya Surapaneni, Samira Bell, Juan Jesús Carrero, Gabriel Chodick et al. · 2022 · Diabetes Care
15. Prevention of cardiorenal complications in people with type 2 diabetes and obesity
    Daniel J. Drucker · 2024 · Cell Metabolism
16. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025)
    Yusuke Ohya, Kimika Arakawa, Naoko Arata, Shuji Arima, Hisatomi Arima, K. Asayama, Yasuaki Dohi, Ako Fukami, Masato Furuhashi, Kenichi Goto et al. · 2026 · Hypertension Research
17. Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline
    Charles Tomson, Alfred K. Cheung, Johannes F.E. Mann, Tara I. Chang, William C. Cushman, Susan L. Furth, Fan Fan Hou, Greg A. Knoll, Paul Muntner, Roberto Pecoits‐Filho et al. · 2021 · Annals of Internal Medicine
18. Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
    Ning Li, Dan Lv, Zhu X, Ping Wei, Yuan Gui, Shijia Liu, Enchao Zhou, Min Zheng, Dong Feng Zhou, Lu Zhang · 2021 · Frontiers in Medicine
19. Aldosterone and cardiovascular diseases
    Wasita Warachit Parksook, Gordon H. Williams · 2022 · Cardiovascular Research
20. Review of Urate-Lowering Therapeutics: From the Past to the Future
    Christopher Jenkins, Jennifer H. Hwang, Jeffrey B. Kopp, Cheryl Ann Winkler, Sung Kweon Cho · 2022 · Frontiers in Pharmacology
21. Nephron overload as a therapeutic target to maximize kidney lifespan
    Valérie A. Luyckx, Andrew D. Rule, Katherine R. Tuttle, Pierre Delanaye, Helen Liapis, Afschin Gandjour, Paola Romagnani, Hans‐Joachim Anders · 2021 · Nature Reviews Nephrology
22. Heart Failure and Cardiorenal Syndrome: A Narrative Review on Pathophysiology, Diagnostic and Therapeutic Regimens—From a Cardiologist’s View
    Angelos C. Mitsas, Mohamed Elzawawi, Sophie I. Mavrogeni, Michael Boekels, Asim Ali Khan, Mahmoud Eldawy, Ioannis Stamatakis, Dimitrios Kouris, Baraa Daboul, Oliver Gunkel et al. · 2022 · Journal of Clinical Medicine
23. Magnetic Resonance Imaging to Evaluate Kidney Structure, Function, and Pathology: Moving Toward Clinical Application
    Susan Francis, Nicholas M. Selby, Maarten W. Taal · 2023 · American Journal of Kidney Diseases
24. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA
    Patrick Barry Mark, Pantelis A. Sarafidis, Robert Ekart, Charles Joseph Ferro, Olga C. Balafa, Beatriz Fernández‐Fernández, William Guy Herrington, Patrick Rossignol, Lucia Del Vecchio, José Manuel Valdivielso et al. · 2023 · Nephrology Dialysis Transplantation
25. Renin-Angiotensin System: Updated Understanding and Role in Physiological and Pathophysiological States
    Ashok Kumar Kanugula, Jasleen Kaur, Jaskaran Batra, Anvitha Reddy Ankireddypalli, Ravikanth Velagapudi · 2023 · Cureus
26. Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression
    Brendon Lange Neuen, Misghina Weldegiorgis, William Guy Herrington, Toshiaki Ohkuma, Margaret C Smith, Mark Woodward · 2021 · American Journal of Kidney Diseases
27. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
    Zhi-Cheng Dai, Jinxia Chen, Rong Zou, Xuan-Bing Liang, Ji‐Xin Tang, Cuiwei Yao · 2023 · Frontiers in Immunology
28. DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
    Handelsman, Yehuda, Anderson, John E., Bakris, George L., Ballantyne, Christie M., Beckman, Joshua A., Bhatt, Deepak L., Bloomgarden, Zachary T., Bozkurt, Biykem, Budoff, Matthew J., Butler, Javed et al. · 2022 · Journal of Diabetes and its Complications
29. Cardiac Structure and Function Across the Spectrum of Aldosteronism: the Atherosclerosis Risk in Communities Study
    Jenifer Michelle Brown, Magnus Olof Wijkman, Brian Lee Claggett, Amil M. Shah, Christie Mitchell Ballantyne, Josef Coresh, Morgan Erika Grams, Zhiying Wang, Bing Yu, Eric Boerwinkle et al. · 2022 · Hypertension
30. Rethinking Chronic Kidney Disease in the Aging Population
    Gaetano Alfano, Rossella Perrone, Francesco Fontana, Giulia Ligabue, Silvia Giovanella, Annachiara Ferrari, Mariacristina Gregorini, Gianni Cappelli, Riccardo Magistroni, Gabriele Donati · 2022 · Life
31. Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
    Dong‐Lim Kim, Seung‐Eun Lee, Nan Hee Kim · 2023 · Endocrinology and Metabolism
32. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial
    Heerspink, Hiddo J.L., Birkenfeld, Andreas L., Cherney, David Z.I., Colhoun, Helen M., Ji, Linong, Mathieu, Chantal, Groop, Per-Henrik, Pratley, Richard E., Rosas, Sylvia E., Rossing, Peter et al. · 2023 · Diabetes Research and Clinical Practice
33. Combination therapy: an upcoming paradigm to improve kidney and cardiovascular outcomes in chronic kidney disease
    Radica Z. Alicic, Joshua J. Neumiller, Katherine R. Tuttle · 2025 · Nephrology Dialysis Transplantation
34. Heart Failure: An Update from the Last Years and a Look at the Near Future
    Mauro Riccardi, Antonio Maria Sammartino, Massimo Francesco Piepoli, Marianna Adamo, Matteo Pagnesi, Giuseppe M.C. Rosano, Marco Metra, Stephan von Haehling, Daniela Tomasoni · 2022 · ESC Heart Failure
35. Kidney fibrosis: Emerging diagnostic and therapeutic strategies
    Barbara M. Klinkhammer, Peter Boor · 2023 · Molecular Aspects of Medicine
36. Aldosterone and aldosterone synthase inhibitors in cardiorenal disease
    Subodh Verma, Avinash Pandey, Arjun K. Pandey, Javed Butler, John S. Lee, Hwee Teoh, C. David Mazer, Mikhail Kosiborod, Francesco Cosentino, Stefan D. Anker et al. · 2023 · American Journal of Physiology-Heart and Circulatory Physiology
37. Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities
    Francesco Patera, Leonardo Gatticchi, Barbara Cellini, Davide Chiasserini, Gianpaolo Reboldi · 2024 · Biomolecules
38. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease
    Alberto Ortíz, Charles Joseph Ferro, Olga C. Balafa, Michel Burnier, Robert Ekart, Jean‐Michel Halimi, Reinhold Hugo Kreutz, Patrick Barry Mark, Alexandre Persu, Patrick Rossignol et al. · 2021 · Nephrology Dialysis Transplantation
39. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association
    Alberto Ortíz, Christoph Wanner, Ron T. Gansevoort, Alberto Ortíz, Christoph Wanner, Ron T. Gansevoort, Mario Gennaro Cozzolino, Danilo Fliser, Giovanni Gambaro, Albert C.M. Ong et al. · 2022 · Nephrology Dialysis Transplantation
40. Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3 −/− Mice
    Zhihui Zhu, Karoline Rosenkranz, Yoshihiro Kusunoki, Chenyu Li, Martin Klaus, Oliver Groß, Maria Lucia Angelotti, Giulia Antonelli, Luigi Cirillo, Paola Romagnani et al. · 2023 · Journal of the American Society of Nephrology
41. Preventing chronic kidney disease and maintaining kidney health: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
    Alberto Ortíz, José Manuel Arreola Guerra, Juliana C.N. Chan, Vivekanand Jha, Holly Kramer, Susanne B. Nicholas, Meda E. Pavkov, Christoph Wanner, Leslie P. Wong, Michael Cheung et al. · 2025 · Kidney International
42. Chronic kidney disease in patients with diabetes mellitus
    Espen Nordheim, Trond Geir Jenssen · 2021 · Endocrine Connections
43. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results
    Rajiv Agarwal, Stefan D. Anker, Gerasimos S Filippatos, Bertram Pitt, Peter R Rossing, Luis Miguel Ruilope, John Boletis, Robert Toto, Guillermo E. Umpierrez, Christoph Wanner et al. · 2021 · Nephrology Dialysis Transplantation
44. Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition)
    Lixin Guo, Xinhua Xiao · 2024 · Aging Medicine
45. Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
    Kenneth W. Mahaffey, Katherine R. Tuttle, Mustafa Arici, Florian M.M. Baeres, George L. Bakris, David M. Charytan, David Z.I. Cherney, Gil Chernin, Ricardo Correa‐Rotter, Janusz Gumprecht et al. · 2024 · European Heart Journal
46. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes
    Pantelis A. Sarafidis, Rajiv Agarwal, Bertram Pitt, Christoph Wanner, Gerasimos S Filippatos, John Boletis, Katherine R. Tuttle, Luis Miguel Ruilope, Peter R Rossing, Robert Toto et al. · 2023 · Clinical Journal of the American Society of Nephrology
47. Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists
    Gianluigi Savarese, Felix Lindberg, Gerasimos S Filippatos, Javed Butler, Stefan D. Anker · 2023 · Diabetologia
48. Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial
    Richard F. Hobbs, Richard J. McManus, Clare J Taylor, Nicholas Robert Jones, Joy K Rahman, Jane L. Wolstenholme, Sungwook Kim, Joseph Kwon, Louise Jones, Jennifer A. Hirst et al. · 2024 · Nature Medicine
49. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials
    Jui‐Yi Chen, Tsuen‐Wei Hsu, Jung-Hua Liu, Heng‐Chih Pan, Chun‐Fu Lai, Shao‐Yu Yang, Vin‐Cent Wu · 2025 · American Journal of Kidney Diseases
50. Mineralocorticoid receptor in cardiovascular diseases—Clinical trials and mechanistic insights
    Johann K Bauersachs, Natalia López‐Andrés · 2021 · British Journal of Pharmacology
51. Stem cell-derived and circulating exosomal microRNAs as new potential tools for diabetic nephropathy management
    Lei Peng, Yu Chen, Shaoqing Shi, Heling Wen · 2022 · Stem Cell Research & Therapy
52. Targeting inflammation for the treatment of Diabetic Kidney Disease: a five-compartment mechanistic model
    Alexis Hofherr, Julie H. Williams, Li‐Ming Gan, Magnus P. Söderberg, Pernille Hansen, Kevin J. Woollard · 2022 · BMC Nephrology
53. Contemporary review of IgA nephropathy
    Edward John Filippone, Rakesh Gulati, John L. Farber · 2024 · Frontiers in Immunology
54. Kidney Fibrosis: Fundamental Questions, Challenges, and Perspectives
    You-Hua Liu · 2024 · Integrative Medicine in Nephrology and Andrology
55. The diuretic effects of SGLT2 inhibitors: A comprehensive review of their specificities and their role in renal protection
    Pierre Delanaye, André Jacques Scheen · 2021 · Diabetes & Metabolism
56. Structural and molecular determinants of mineralocorticoid receptor signalling
    Claudia Großmann, Brian Almeida‐Prieto, Alexander Nolze, Diego Álvarez de la Rosa · 2021 · British Journal of Pharmacology
57. Faecal Microbiota Transplantation and Chronic Kidney Disease
    Ji Bian, Ann D. Liebert, Brian T. Bicknell, Xinming Chen, Chunling Huang, Carol A. Pollock · 2022 · Nutrients
58. Hyperkalemia in Chronic Kidney Disease: Links, Risks and Management
    Alexander Sarnowski, Rouvick Mariano Gama, Alec Dawson, Hannah Mason, Debasish Banerjee · 2022 · International Journal of Nephrology and Renovascular Disease
59. Nonsteroidal Mineralocorticoid Receptor Antagonism by Finerenone—Translational Aspects and Clinical Perspectives across Multiple Organ Systems
    Peter Kolkhof, Robert Lawatscheck, Gerasimos S Filippatos, George L. Bakris · 2022 · International Journal of Molecular Sciences
60. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature
    Panagiotis I. Georgianos, Rajiv Agarwal · 2022 · American Journal of Hypertension
61. DNA methylation markers for kidney function and progression of diabetic kidney disease
    Kelly Yichen Li, Claudia H.T. Tam, Hongbo Liu, Samantha E. Day, Cadmon K.P. Lim, Wing Yee So, Chuiguo Huang, Guozhi Jiang, Mai Shi, Heung Man Lee et al. · 2023 · Nature Communications
62. A Review on Diabetic Retinopathy
    Vijender Kour, Jayshree Swain, Jaspreet Singh, Hershdeep Singh, Harvinder Kour · 2023 · Current Diabetes Reviews
63. Update on the Pathogenesis, Diagnosis, and Treatment of Diabetic Tubulopathy
    Danfeng Liu, Xiaojie Chen, Weiting He, Min Lu, Qiuling Li, Shaogui Zhang, Jianteng Xie, Yifan Zhang, Weimin Wang · 2024 · Integrative Medicine in Nephrology and Andrology
64. Diabetic Proteinuria Revisited: Updated Physiologic Perspectives
    Samuel Noam Heyman, Itamar Raz, Jamie P. Dwyer, Roni Weinberg Sibony, Julia Breyer Lewis, Zaid A. Abassi · 2022 · Cells
65. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
    Ndumele, Chiadi E., Rodriguez, Fatima, Dixon, Dave L., Khan, Sadiya S., Mukherjee, Debabrata, Bajaj, Mandeep, Bangalore, Sripal, Bozkurt, Biykem, Breathett, Khadijah, Clarke, Shoa L. et al. · 2026 · JACC
66. Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies
    José Manuel Valdivielso, Olga C. Balafa, Robert Ekart, Charles Joseph Ferro, Francesca Mallamaci, Patrick Barry Mark, Patrick Rossignol, Pantelis A. Sarafidis, Lucia Del Vecchio, Alberto Ortíz · 2021 · Drugs
67. Chronic kidney disease in children: an update
    Luigi Cirillo, Letizia De Chiara, Samantha Innocenti, Carmela Errichiello, Paola Romagnani, Francesca Becherucci · 2023 · Clinical Kidney Journal
68. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials
    Alireza Oraii, Jeff S. Healey, Krzysztof Kowalik, Avinash K Pandey, Alexander Philipp Benz, Jorge A. Wong, David Conen, William F. McIntyre · 2024 · European Heart Journal
69. SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application
    Jae Hyun Bae · 2025 · Diabetes & Metabolism Journal
70. SGLT2 inhibition requires reconsideration of fundamental paradigms in chronic kidney disease, ‘diabetic nephropathy’, IgA nephropathy and podocytopathies with FSGS lesions
    Hans‐Joachim Anders, Anna Julie Peired, Paola Romagnani · 2020 · Nephrology Dialysis Transplantation
71. Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study
    Aimin Yang, Mai Shi, Eric S. H. Lau et al. · 2022 · EClinicalMedicine
72. Efficacy and safety of drugs for people with type 2 diabetes mellitus and chronic kidney disease on kidney and cardiovascular outcomes: A systematic review and network meta-analysis of randomized controlled trials
    Qing Yang, Yanlin Lang, Wenjie Yang, Fenghao Yang, Jia Yang, Yucheng Wu, Xiang Xiao, Chunmei Qin, Yutong Zou, Yuancheng Zhao et al. · 2023 · Diabetes Research and Clinical Practice
73. Aging and chronic kidney disease: epidemiology, therapy, management and the role of immunity
    Yukun Tang, Jipin Jiang, Yuanyuan Zhao, Dunfeng Du · 2024 · Clinical Kidney Journal
74. Novel Therapies for Alport Syndrome
    Efren Chavez, Juanly Rodriguez, Yelena R. Drexler, Alessia Fornoni · 2022 · Frontiers in Medicine
75. Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial
    Frederik Husum Mårup, Martin Bjergskov Thomsen, Henrik Birn · 2023 · Clinical Kidney Journal
76. Adverse Effects of Aldosterone: Beyond Blood Pressure
    Jenifer Michelle Brown · 2024 · Journal of the American Heart Association
77. Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection
    Alessio Mazzieri, Francesca Porcellati, Francesca Timio, Gianpaolo Reboldi · 2024 · International Journal of Molecular Sciences
78. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations
    Jay H. Shubrook, Joshua J. Neumiller, Eugene E. Wright · 2021 · Postgraduate Medicine
79. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
    Ulrich Kintscher, Frank Edelmann · 2023 · Cardiovascular Diabetology
80. Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks
    Nathan Mullen, James M. G. Curneen, Padraig T. Donlon, Punit Prakash, Irina Bancos, Mark Gurnell, Michael Conall Dennedy · 2023 · Endocrine Reviews
81. Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
    Jonatan Barrera‐Chimal, Peter Kolkhof, Ixchel Lima‐Posada, Joachim Alexandre, Patrick Rossignol, Frédéric Jaisser · 2021 · Expert Opinion on Investigational Drugs
82. Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist's point of view
    Murilo Henrique Guedes, Roberto Pecoits‐Filho · 2021 · Journal of Internal Medicine
83. Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx
    Michael Crompton, Joanne Ferguson, Raina Devi Ramnath, Karen L. Onions, Anna S. Ogier, Monica Gamez, Colin J. Down, Laura Skinner, KHF Wong, Lauren Kari Dixon et al. · 2023 · JCI Insight
84. Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded db/db Mice
    Daigoro Hirohama, Mitsuhiro Nishimoto, Nobuhiro Ayuzawa, Wakako Kawarazaki, Wataru Fujii, Shigeyoshi Oba, Shigeru Shibata, Takeshi Marumo, Toshiro Fujita · 2021 · Hypertension
85. Advances in understanding and treating diabetic kidney disease: focus on tubulointerstitial inflammation mechanisms
    Chengren Xu, Xiaowen Ha, Shufen Yang, Xuefei Tian, Hong Jiang · 2023 · Frontiers in Endocrinology
86. Renin–Angiotensin–Aldosterone System: From History to Practice of a Secular Topic
    Sara Helena Ksiazek, Lilio Hu, Sebastiano Andò, Markus Pirklbauer, Marcus D. Säemann, Chiara Ruotolo, Gianluigi Zaza, Gaetano La Manna, Luca De Nicola, Gert J. Mayer et al. · 2024 · International Journal of Molecular Sciences
87. Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2024
    Shu-Yang ZHANG · 2025 · 老年心脏病学杂志：英文版
88. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
    Chiadi E. Ndumele, Fátima Rodríguez, Dave L. Dixon, Sadiya S. Khan, Debabrata Mukherjee, Mandeep Singh Bajaj, Sripal Bangalore, Biykem Bozkurt, Khadijah K Breathett, Shoa L. Clarke et al. · 2026 · Circulation
89. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD
    Amy K. Mottl, Radica Z. Alicic, Christos Argyropoulos, Frank Chip Brosius, Michael S. Mauer, Mark E. Molitch, Robert G. Nelson, Leigh Perreault, Susanne B. Nicholas · 2022 · American Journal of Kidney Diseases
90. Information and consensus document for the detection and management of chronic kidney disease
    Rafael García Maset, Jordi Bover, J. Segura, Marian Goicoechea Diezhandino, Jesús Cebollada del Hoyo, Javier Escalada, Lorenzo Fácila, Javier Gamarra, José Antonio García‐Donaire, Lisardo García Matarin et al. · 2022 · Nefrología (English Edition)
91. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of the European Renal Association
    Alberto Ortíz, Christoph Wanner, Ron T. Gansevoort, Alberto Ortíz, Christoph Wanner, Ron T. Gansevoort, Mario Gennaro Cozzolino, Danilo Fliser, Giovanni Gambaro, Albert C.M. Ong et al. · 2022 · European Journal of Preventive Cardiology
92. Renal fibrosis as a hallmark of diabetic kidney disease: potential role of targeting transforming growth factor-beta (TGF-β) and related molecules
    Jiali Tang, Fang Liu, Mark Emmanuel Cooper, Zhonglin Chai · 2022 · Expert Opinion on Therapeutic Targets
93. Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist
    Luca Di Lullo, Carlo Lavalle, Alessia Scatena, Marco Valerio Mariani, Claudio Ronco, Antonio Bellasi · 2023 · Journal of Clinical Medicine
94. People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action
    Hiddo JL Heerspink, David Z.I. Cherney, Per‐Henrik Groop, Chantal Matthieu, Peter R Rossing, Katherine R. Tuttle, Janet B. McGill · 2023 · The Lancet Diabetes & Endocrinology
95. Routine Spironolactone in Acute Myocardial Infarction
    Sanjit S. Jolly, Marc-André d’Entremont, Bertram Pitt, Shun Fu Lee, Rajibul Islam Mian, Jessica Tyrwhitt, Sasko Kedev, Gilles Montalescot, Jan Hein Cornel, Goran R. Stankovic et al. · 2024 · New England Journal of Medicine
96. Phillygenin improves diabetic nephropathy by inhibiting inflammation and apoptosis via regulating TLR4/MyD88/NF-κB and PI3K/AKT/GSK3β signaling pathways
    Qi Feng, Xiaoyue Yu, Junwei Xie, Fengxun Liu, Xiaonan Zhang, Shiyang Li, Yixue Wang, Shaokang Pan, Dongwei Liu, Zhangsuo Liu · 2024 · Phytomedicine
97. KDIGO 2024 clinical practice guideline on evaluation and management of chronic kidney disease: A primer on what pharmacists need to know
    Linda Awdishu, Rebecca Maxson, Chelsea Gratt, Tamara T. Rubenzik, Marisa Battistella · 2025 · American Journal of Health-System Pharmacy
98. The role of endoplasmic reticulum–mitochondria-associated membranes in diabetic kidney disease
    Ahmed Elwakiel, Akash Mathew, Berend Isermann · 2023 · Cardiovascular Research
99. An Update on Current Therapeutic Options in IgA Nephropathy
    Regina Shaoying Lim, See Cheng Yeo, Jonathan Barratt, Dana V. Rizk · 2024 · Journal of Clinical Medicine
100. JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
     Akira Fujiyoshi, Shun Kohsaka, Jun Hata, Mitsuhiko Hara, Hisashi Kai, Daisaku Masuda, Naomi Miyamatsu, Yoshihiko Nishio, Masatsune Ogura, Masataka Sata et al. · 2024 · Circulation Journal